| Item |
Information |
|
Drug Groups
|
approved |
|
Description
|
A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as a loop or high ceiling diuretic. [PubChem] |
| Indication |
For the treatment of high blood pressure and edema caused by diseases like congestive heart failure, liver failure, and kidney failure. |
| Pharmacology |
Ethacrynic acid is a monosulfonamyl loop or high ceiling diuretic. Ethacrynic acid acts on the ascending limb of the loop of Henle and on the proximal and distal tubules. Urinary output is usually dose dependent and related to the magnitude of fluid accumulation. Water and electrolyte excretion may be increased several times over that observed with thiazide diuretics, since ethacrynic acid inhibits reabsorption of a much greater proportion of filtered sodium than most other diuretic agents. Therefore, ethacrynic acid is effective in many patients who have significant degrees of renal insufficiency. Ethacrynic acid has little or no effect on glomerular filtration or on renal blood flow, except following pronounced reductions in plasma volume when associated with rapid diuresis. |
| Toxicity |
Overdosage may lead to excessive diuresis with electrolyte depletion. |
| Affected Organisms |
| • |
Humans and other mammals |
|
| Biotransformation |
Hepatic. |
| Absorption |
Onset of action is rapid, usually within 30 minutes after an oral dose of ethacrynic acid or within 5 minutes after an intravenous injection of ethacrynic acid. |
| Protein Binding |
> 98% |
| External Links |
|